Xie Wanqing, Zhou Lijiang, Li Shan, Hui Tianqian, Chen Di
Department of Biochemistry, Rush University Medical Center, Chicago, Illinois.
Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Ann N Y Acad Sci. 2016 Jan;1364(1):25-31. doi: 10.1111/nyas.12968. Epub 2015 Dec 2.
Spondyloarthritis (SpA) is a group of diseases consisting of psoriatic arthritis (PsA), reactive arthritis, arthritis related to inflammatory bowel disease (a subgroup of juvenile idiopathic arthritis), and ankylosing spondylitis (the prototype of SpA). Axial bone formation and the combination of concurrent erosion and new bone formation are specific characteristics of SpA disease. The use of antiproinflammatory cytokines, such as inhibitors of tumor necrosis factor α (TNF-α), appears to be the greatest advance in the treatment of SpA over the past 20 years. However, TNF-α blockers do not halt new bone formation. Recent clinical observations and animal studies demonstrate that Wnt signaling proteins and natural Wnt inhibitors, such as DKK1 and sclerostin, are likely to play important roles in the process of ankylosis in SpA, and could potentially serve as therapeutic targets for the treatment of SpA.
脊柱关节炎（SpA）是一组疾病，包括银屑病关节炎（PsA）、反应性关节炎、与炎症性肠病相关的关节炎（青少年特发性关节炎的一个亚组）和强直性脊柱炎（SpA的原型）。轴向骨形成以及同时存在的侵蚀和新骨形成的组合是SpA疾病的特定特征。使用抗炎症细胞因子，如肿瘤坏死因子α（TNF-α）抑制剂，似乎是过去20年中SpA治疗方面最大的进展。然而，TNF-α阻滞剂并不能阻止新骨形成。最近的临床观察和动物研究表明，Wnt信号蛋白和天然Wnt抑制剂，如DKK1和硬化蛋白，可能在SpA的关节强硬过程中起重要作用，并有可能成为SpA治疗的靶点。
